Lineage Cell Therapeutics Inc (LCTX) — Cash Flow Reinvestment Rate
Lineage Cell Therapeutics Inc (LCTX) has a Cash Flow Reinvestment Rate of 0.00x as of March 2022, reinvesting $92.00K (capex $46.00K plus investments $-46.00K) from operating cash flow of $21.90 Million. See Lineage Cell Therapeutics Inc free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Lineage Cell Therapeutics Inc Cash Flow Reinvestment Rate (2022–2022)
Historical reinvestment intensity for Lineage Cell Therapeutics Inc across 1 annual periods. For the full cash flow conversion analysis, see LCTX cash flow conversion.
Annual Cash Flow Reinvestment Rate for Lineage Cell Therapeutics Inc (2022–2022)
Year-by-year capital reinvestment analysis for Lineage Cell Therapeutics Inc. See LCTX FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (USD) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2022 | 43.59x | $46.16 Million | $1.06 Million | $413.00K | — |